Mirati’s KRAS-blocking Lung Cancer Drug Clears Safety Hurdle in Combination Study
Mirati Therapeutics said this week that its KRAS-targeting cancer drug adagrasib combined with another immunotherapy was well-tolerated by lung cancer patients.
Tag: lung cancer
All
Latest
All
Latest
Lung Cancer: Lumakras Cuts Risk by 34%
Amgen's Lumakras pill reduced the risk of disease progression in patients with advanced lung cancer by 34% compared with chemotherapy in a clinical trial, the company said on Sunday.
All
Latest
Merck Ends Lung Cancer Berzosertib Trial to Consider Future of ATR Inhibitor
Merck is ending a clinical trial for berzosertib, an ATR inhibitor that was once considered a promising treatment in its oncology program.
Salk Scientists Receive 2022 Endeavor Award to Study Lung Cancer
A group of Salk scientists received a 2022 Mark Foundation for Cancer Research Endeavor Award to support their research exploring the metabolic changes that help lung cancers develop.
Read More
The Role of in vivo Cellular Imaging in Managing Lung Disease
Although the technology is relatively new, there is a growing body of research that demonstrates the efficacy of confocal laser endomicroscopy (CLE), illustrating its broad application and future potential.
Read More
Medicare Update Will Increase Access to Lung Cancer Screening
An update to the CMS lung cancer screening eligibility guidelines will result in more Americans eligible to receive lifesaving lung cancer screenings at no cost, the American Lung Association says.
Read More
Radon Found in 1-in-15 American Homes
The American Lung Association released a 5-year action plan to limit radon exposure, the second leading cause of lung cancer in the United States.
Read More
Blood Test Helps Predict Who May Benefit From Lung Cancer Screening
A blood test, combined with a risk model based on an individual’s history, more accurately determines who is likely to benefit from lung cancer screening than the current U.S. recommendation, according to a study published in the Journal of Clinical Oncology.
Read More
40% of Stroke Survivors Continue to Smoke
Stroke survivors with a history of smoking were 28% less likely to have quit smoking compared to cancer survivors.
Read More
New Pricing Program Takeda Alunbrig
Takeda recently launched a value-based pricing program for its lung cancer drug Alunbrig.
Read More
Immunotherapy in Malignant Pleural Mesothelioma
New data confirm combination nivolumab and ipilimumab as the best treatment for unresectable malignant pleural mesothelioma.
Read More
FDA Approves Tecentriq for Early NSC Lung Cancer
The FDA has approved atezolizumab (brand name Tecentriq, Genetech) as adjuvant treatment following surgery and platinum-based chemotherapy for adults with Stage II-IIIA non-small cell lung cancer.
Read More
Disseminated Coccidioidomycosis Mimics Lung Cancer
A case study presented at Chest 2021 reports that the fungal infection coccidioidomycosis may have varied clinical presentations, including mimicking lung cancer.
Read More
Nasopharyngeal Cancer Incidence Varies Widely Among Different Ethnic Groups
Chinese Americans and Laotian Americans were over 10 and 14 times more likely to be diagnosed with nasopharyngeal cancer, respectively, than non-Hispanic white Americans.
Read More
Black Lung Cancer Patients Receiving Immunotherapy May Fare Better Than White Patients
Black patients experience higher lung cancer mortality than white patients, but equal access to immunotherapy may help close the gap.
Read More